There are currently 237 clinical trials in Hartford, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis and Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
NCT06102174
Recruiting
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months. These children have Lower Respiratory Tract Infection (LRTI) caused by Respiratory Syncytial Virus (RSV). LRTI is the infection to the lower airways such as lungs. This study will help inform the amount of sisunatovir to be used in future studies of sisunatovir in children. This study is seeking for participants who: Are 1 day to less than or equal to 60 mo... Read More
Gender:
All
Ages:
Between 1 day and 60 months
Trial Updated:
05/31/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
OSA-18 in Children With Mild Obstructive Sleep Apnea: Can it be a Helpful Decision Making Tool?
NCT05911646
Recruiting
The concept is a novel research idea that incorporates the potential impact of patient quality of life (QOL) on decision-making for treatment of mild obstructive sleep apnea (OSA). Our hypothesis is that in children with mild OSA there is significant conflict with parental decision-making; in the absence of significant sleep apnea, there is limited research regarding comparative efficacy of various treatment options. The impact of a QOL questionnaire can be a significant deciding factor and may... Read More
Gender:
All
Ages:
Between 3 years and 12 years
Trial Updated:
05/30/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Apnea, Obstructive Sleep, Obstructive Sleep Apnea
Register for Updates
Do Probiotics Improve Recovery From Acute Constipation in Kids?
NCT05734833
Recruiting
The purpose of this study is to evaluate the potential benefit of adding probiotics to the standard treatment for children who present to the emergency department with acute constipation. Before evaluating probiotics as a single therapy, the investigators believe it is prudent to evaluate for added benefit first. Specifically, they seek to determine if adding probiotics decreases the length of time to normal stool frequency, decreases the number of days with abdominal pain/cramping, and improves... Read More
Gender:
All
Ages:
Between 6 months and 8 years
Trial Updated:
05/29/2024
Locations: Connecticut Chidlren's Medical Center, Hartford, Connecticut
Conditions: Constipation
Register for Updates
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
05/29/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
NCT06096779
Recruiting
The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Hartford Healthcare Cancer Institute at Hartford Hospital, Hartford, Connecticut
Conditions: Hepatocellular Carcinoma
Register for Updates
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT05912244
Recruiting
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut
Conditions: Melanoma
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
All
Ages:
30 years and above
Trial Updated:
05/28/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.
Gender:
All
Ages:
Between 2 years and 19 years
Trial Updated:
05/27/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Hartford Hospital (HH), Hartford, Connecticut
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT06079372
Recruiting
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
05/23/2024
Locations: Research Site, Hartford, Connecticut
Conditions: Hypophosphatasia
Register for Updates
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612
Recruiting
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut
Conditions: Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
Register for Updates
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
NCT04137107
Recruiting
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Gender:
All
Ages:
25 years and above
Trial Updated:
05/22/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Register for Updates